Masimo Co. (MASI) Shares Bought by Los Angeles Capital Management & Equity Research Inc.

Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Masimo Co. (NASDAQ:MASI) by 26.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 137,145 shares of the medical equipment provider’s stock after buying an additional 29,104 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned about 0.26% of Masimo worth $17,080,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in MASI. FMR LLC raised its position in shares of Masimo by 6,605.4% during the 2nd quarter. FMR LLC now owns 1,821,994 shares of the medical equipment provider’s stock worth $177,918,000 after purchasing an additional 1,794,822 shares during the period. American Century Companies Inc. raised its position in shares of Masimo by 932.6% during the 3rd quarter. American Century Companies Inc. now owns 850,436 shares of the medical equipment provider’s stock worth $105,913,000 after purchasing an additional 768,078 shares during the period. Schroder Investment Management Group raised its position in shares of Masimo by 77.2% during the 2nd quarter. Schroder Investment Management Group now owns 799,435 shares of the medical equipment provider’s stock worth $106,225,000 after purchasing an additional 348,169 shares during the period. Victory Capital Management Inc. raised its position in shares of Masimo by 43.4% during the 3rd quarter. Victory Capital Management Inc. now owns 641,074 shares of the medical equipment provider’s stock worth $79,838,000 after purchasing an additional 194,055 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Masimo by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 552,626 shares of the medical equipment provider’s stock worth $53,964,000 after purchasing an additional 41,126 shares during the period. 83.22% of the stock is currently owned by institutional investors.

In other news, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $113.14, for a total transaction of $226,280.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Bilal Muhsin sold 20,000 shares of Masimo stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $117.75, for a total value of $2,355,000.00. Following the transaction, the executive vice president now owns 10,000 shares in the company, valued at $1,177,500. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 666,033 shares of company stock worth $79,900,568. 12.60% of the stock is owned by insiders.

Several analysts recently commented on MASI shares. Stifel Nicolaus raised their target price on Masimo from $112.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. BidaskClub cut Masimo from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 3rd. Needham & Company LLC started coverage on Masimo in a research report on Friday, September 14th. They issued a “buy” rating on the stock. Piper Jaffray Companies raised their target price on Masimo to $120.00 and gave the company a “neutral” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research cut Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $114.40.

MASI opened at $115.49 on Friday. Masimo Co. has a 12 month low of $80.69 and a 12 month high of $126.89. The company has a market capitalization of $6.23 billion, a P/E ratio of 40.39, a price-to-earnings-growth ratio of 2.76 and a beta of 1.11.

Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 EPS for the quarter, beating the consensus estimate of $0.69 by $0.02. Masimo had a return on equity of 20.29% and a net margin of 17.08%. The firm had revenue of $210.58 million for the quarter, compared to analysts’ expectations of $207.62 million. During the same period last year, the firm earned $0.56 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. Equities analysts anticipate that Masimo Co. will post 2.92 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/11/10/masimo-co-masi-shares-bought-by-los-angeles-capital-management-equity-research-inc.html.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply